



Contact: Julie Bryant  
VP Business Development and Marketing  
GeneGo, Inc.  
(858) 756 7996  
julie@genego.com

## **GLAXOSMITHKLINE EXTENDS GENEGO LICENSE AND ADDS NEW PRODUCTS**

**St. Joseph, MI. February 5th, 2008** –GeneGo, Inc., the leading systems biology tools company, announced today that GlaxoSmithKline has extended their licensing agreement with GeneGo and have added additional capability. This will provide GlaxoSmithKline researchers with global access to MetaCore, MapEditor and MetaBase. MetaCore is GeneGo’s flagship platform for functional analysis of biological OMICs data featuring a comprehensive collection of pathway maps and network models for cellular processes and common diseases. MetaCore is used for target identification, validation, biomarker discovery and knowledge mining. GlaxoSmithKline will also use the platform as a repository of all types of experimental data as well as resulting analyses. All of this information can be easily shared with individuals or groups. MetaBase is direct access to the manually curated database of pathways, networks, ontologies, medicinal chemistry and diseases covering human, mouse and rat. MapEditor is a powerful research tool for creating interinteractive custom maps which amalgamate MetaBase knowledge content with proprietary information and data.

“We have a good working relationship with GlaxoSmithKline developing new products such as our pay as you go 1-2-3 Workflow,” said Julie Bryant, GeneGo’s VP of Business development. “We will continue to work closely developing new functionality, tools and content for GlaxoSmithKline.”

### **About GeneGo, Inc.**

GeneGo, Inc. develops systems biology technology such as compound based [pathway analysis](#), cheminformatics & [bioinformatics software](#) for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, [proteomics](#), metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 4.5™, assists pharmaceutical scientists in the areas of target selection and validation, [data mining](#) in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.5™ is designed for prediction of human metabolism, toxicity and biological

effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.

For more information, please visit the company's web site at [www.genego.com](http://www.genego.com).

**MetaCore™, MetaBase™, MetaDrug™, MetaLink™, MetaDiscovery™, MetaTox™, MetaMiner™ and 1-2-3 Workflow™ are trademarks of GeneGo, Inc.**